Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer.
Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Verhaak, R. G. W. et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
With this method, we identified two clinically relevant subtypes of GBM: the 'Classical-like subtype' (CL) characterised by EGFR-positive, p53-negative and PDGFRA-negative staining and the 'Proneural-like subtype' (PNL) characterised by p53- and/or PDGFRA-positive staining.
Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Studies of the molecular profiles of breast cancers have indicated that breast tumors can be classified into five etiologically and prognostically relevant subtypes on the basis of gene expression patterns [ 1].
In most cases, iPSCs were differentiated into disease-relevant subtypes of cells exhibiting certain disease features.
By applying a bioinformatics approach we identified genes co-regulated with IL6 expression in clinically-relevant subtypes of EOC, their interactions in networks and pathways as well as their functional association to growth factor response.
Gene expression studies have identified clinically-relevant subtypes of DLBCL, showing that patients with a germinal centre-derived tumour have an improved prognosis compared to those with a non-germinal centre-derived tumour (Alizadeh et al, 2000; Rosenwald et al, 2002).
Breast cancer is classified into clinically relevant subtypes based on the expression of the oestrogen receptor (ER), classifying tumours into ER positive and ER negative cases.
